SPRB - Spruce Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Daly City,
United States
Type: Equity
SPRB price evolution
SPRB
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $69.68 | $81.15 | $96.34 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $63.57 | $73.91 | $85.86 | $102.18 |
| Long term investments | ||||
| Property, plant & equipment | $1 | $1.06 | $1.12 | $1.18 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.61 | $1.67 | $1.76 | |
| Total investments | ||||
| Total assets | $65.1 | $75.52 | $87.54 | $103.95 |
| Current liabilities | ||||
| Accounts payable | $1.8 | $0.68 | $1.89 | $3.33 |
| Deferred revenue | $1.3 | $2.91 | $4.91 | |
| Short long term debt | $1.62 | $1.62 | $1.62 | |
| Total current liabilities | $11.86 | $14.29 | $18.39 | $24.46 |
| Long term debt | $0.52 | $1.8 | $2.27 | $2.74 |
| Total noncurrent liabilities | $2.06 | $2.52 | $2.97 | |
| Total debt | $3.42 | $3.89 | $4.36 | |
| Total liabilities | $13.46 | $16.35 | $20.91 | $27.44 |
| Shareholders' equity | ||||
| Retained earnings | -$226.71 | -$218.04 | -$208.86 | -$197.23 |
| Other shareholder equity | ||||
| Total shareholder equity | $59.17 | $66.62 | $76.51 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $96.34 | $24.49 | $42.96 | $157.37 |
| Short term investments | $54.59 | $46.22 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $102.18 | $83.61 | $91.89 | $160.4 |
| Long term investments | $32.46 | |||
| Property, plant & equipment | $1.18 | $1.4 | $1.48 | $1.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.76 | $2.04 | $34.59 | $2.49 |
| Total investments | $54.59 | $78.68 | ||
| Total assets | $103.95 | $85.65 | $126.49 | $162.88 |
| Current liabilities | ||||
| Accounts payable | $3.33 | $1.43 | $2.82 | $3.63 |
| Deferred revenue | $4.91 | |||
| Short long term debt | $1.62 | $1.62 | $2.55 | |
| Total current liabilities | $24.46 | $12.45 | $8.87 | $9.76 |
| Long term debt | $2.74 | $3.29 | $6.17 | $3.58 |
| Total noncurrent liabilities | $2.97 | $4.71 | $6.24 | $3.69 |
| Total debt | $4.36 | $6.18 | $6.17 | $6.13 |
| Total liabilities | $27.44 | $17.16 | $15.12 | $13.46 |
| Shareholders' equity | ||||
| Retained earnings | -$197.23 | -$149.31 | -$103.13 | -$60.84 |
| Other shareholder equity | -$0.56 | -$0.18 | ||
| Total shareholder equity | $76.51 | $68.49 | $111.37 | $149.43 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.6 | $1.61 | $2 | $2.89 |
| Cost of revenue | ||||
| Gross Profit | $1.61 | $2 | $2.89 | |
| Operating activities | ||||
| Research & development | $8.09 | $10.32 | $11.1 | |
| Selling, general & administrative | $3.56 | $4.32 | $2.95 | |
| Total operating expenses | $10.01 | $11.65 | $14.63 | $14.05 |
| Operating income | -$10.04 | -$12.63 | -$11.16 | |
| Income from continuing operations | ||||
| EBIT | -$10.04 | -$12.63 | -$9.84 | |
| Income tax expense | ||||
| Interest expense | -$0.07 | -$0.85 | -$1.01 | $0.11 |
| Net income | ||||
| Net income | -$8.67 | -$9.18 | -$11.63 | -$9.95 |
| Income (for common shares) | -$9.18 | -$11.63 | -$9.95 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.09 | |||
| Cost of revenue | ||||
| Gross Profit | $10.09 | |||
| Operating activities | ||||
| Research & development | $49.43 | $35.2 | $30.7 | $23.85 |
| Selling, general & administrative | $12.65 | $12.09 | $11.37 | $5.56 |
| Total operating expenses | $62.08 | $47.28 | $42.07 | $29.42 |
| Operating income | -$51.99 | -$47.28 | -$42.07 | -$29.42 |
| Income from continuing operations | ||||
| EBIT | -$47.44 | -$45.76 | -$41.95 | -$29.22 |
| Income tax expense | ||||
| Interest expense | $0.48 | $0.42 | $0.34 | $0.32 |
| Net income | ||||
| Net income | -$47.92 | -$46.18 | -$42.29 | -$29.54 |
| Income (for common shares) | -$47.92 | -$46.18 | -$42.29 | -$29.54 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$9.18 | -$11.63 | -$9.95 | |
| Operating activities | ||||
| Depreciation | $0.07 | $0.07 | $0.07 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.69 | $1.56 | $1.22 | |
| Total cash flows from operations | -$11.11 | -$14.96 | -$11.21 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $9.3 | |||
| Total cash flows from investing | $9.3 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $0.18 | $0.07 | |
| Net borrowings | -$0.41 | -$0.41 | -$0.41 | |
| Total cash flows from financing | -$1 | -$0.36 | -$0.23 | -$0.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$36.28 | -$11.47 | -$15.19 | -$2.46 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$47.92 | -$46.18 | -$42.29 | -$29.54 |
| Operating activities | ||||
| Depreciation | $0.3 | $0.43 | $0.38 | $0.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.62 | $3.63 | $3.96 | $0.76 |
| Total cash flows from operations | -$33.27 | -$41.68 | -$35.88 | -$27.52 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | -$0.09 | -$0.07 |
| Investments | $55.78 | $23.7 | -$79.08 | |
| Total cash flows from investing | $55.78 | $23.69 | -$79.17 | -$0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $53.79 | $0.08 | $0.46 | $96.31 |
| Net borrowings | -$1.62 | $0.22 | ||
| Total cash flows from financing | $49.14 | -$0.24 | $0.64 | $181.03 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $71.64 | -$18.23 | -$114.4 | $153.44 |
News
Fundamentals
| Market cap | $15.28M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 41.30M |
| Revenue | $7.10M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$39.43M |
| Revenue Q/Q | -80.41% |
| Revenue Y/Y | -1.40% |
| P/E ratio | -0.39 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.15 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.95 |
|---|---|
| ROA | -47.49% |
| ROE | N/A |
| Debt/Equity | 0.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.36 |
| Quick ratio | N/A |